Sito Bio(SZ:300583)2023-10-20 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 259.57 million, a decrease of 12.52% compared to CNY 296.71 million in the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was CNY 1.19 million, down 86.73% from CNY 8.97 million year-on-year[4]. - Basic earnings per share for Q3 2023 were CNY 0.01, an 80.00% decrease from CNY 0.05 in the same period last year[4]. - Total revenue for Q3 2023 was CNY 923,225,289.28, a slight decrease of 1.0% compared to CNY 932,952,552.55 in Q3 2022[24]. - Operating profit for the period was CNY 47,511,195.80, down from CNY 53,432,075.32 in the same period last year, reflecting a decrease of approximately 11.0%[24]. - Net profit for Q3 2023 reached CNY 67,810,027.16, an increase of 70.8% compared to CNY 39,712,103.84 in Q3 2022[25]. - Earnings per share (EPS) for Q3 2023 was CNY 0.50, up from CNY 0.24 in the previous year, indicating a significant improvement in profitability[25]. - The company reported a total comprehensive income of CNY 64,376,453.43 for the quarter, compared to CNY 39,029,658.94 in the same period last year, indicating a growth of 64.9%[25]. Cash Flow and Liquidity - The net cash flow from operating activities was negative, amounting to CNY -73.86 million, a decline of 133.23% compared to CNY 271.88 million in the previous year[4]. - Total operating cash flow for the first nine months of 2023 was -73,863,271.88, a decrease of 133.23% compared to 222,249,218.76 in the same period of 2022[10]. - The cash flow from operating activities for the period was -73,863,271.88 CNY, a significant decrease compared to 222,249,218.76 CNY in the previous period[27]. - Cash inflow from operating activities totaled 686,312,122.82 CNY, down from 725,311,572.48 CNY in the previous period[27]. - Cash outflow from operating activities increased to 760,175,394.70 CNY, compared to 503,062,353.72 CNY in the previous period[27]. - The company reported a total cash and cash equivalents balance of 182,627,502.53 CNY at the end of the period, compared to 76,638,079.91 CNY at the end of the previous period[28]. - The company experienced a foreign exchange impact of -4,071,102.05 CNY on cash and cash equivalents[28]. Assets and Liabilities - Total assets as of September 30, 2023, were CNY 3.31 billion, reflecting a 10.50% increase from CNY 2.99 billion at the beginning of the year[4]. - Total assets increased to CNY 3,310,297,963.95, compared to CNY 2,995,678,379.92 at the end of Q3 2022, representing an increase of approximately 10.5%[22]. - Total liabilities remained stable at CNY 1,224,966,635.63, slightly up from CNY 1,224,800,344.70 in the previous year[22]. - The company's equity attributable to shareholders rose to CNY 2,028,266,236.31, an increase of 17.9% from CNY 1,720,136,902.94 in Q3 2022[22]. - The company reported a total of CNY 20,147,819 in newly issued shares, with a total of CNY 22,682,819 in capital raised through various private placements[18]. Inventory and Receivables - The company reported a 39.00% increase in inventory, reaching CNY 846.75 million, attributed to an increase in product variety and inventory reserves[9]. - The company experienced a 33.00% decrease in receivables financing, totaling CNY 59.68 million, due to a reduction in bank acceptance bills received[9]. - Accounts receivable slightly increased to CNY 196,931,778.08 from CNY 196,565,259.17, indicating a marginal growth of 0.19%[21]. - Inventory surged to CNY 846,749,036.69, up from CNY 608,261,782.36, reflecting an increase of about 39%[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,676[12]. - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, amounting to 43,297,382 shares[13]. - The total number of shares subject to lock-up at the beginning of the period was 2,220,000, with 1,332,000 shares released during the current period, resulting in a total of 3,552,000 shares at the end of the period[16]. - The lock-up shares for Kong Qingzhi increased from 315,000 to 504,000 after 189,000 shares were released, indicating a 60% increase in lock-up shares[16]. - Xu Guoxin had 2,278,594 shares added during the current period, with a lock-up period of 6 months starting from April 20, 2023[16]. - Li Lifeng's lock-up shares increased to 1,424,120 after 1,424,120 shares were released, reflecting a full release of previously locked shares[16]. - Zhang Jianfei's lock-up shares reached 1,993,768 after the release of 1,993,768 shares, indicating a complete release of his lock-up[16]. - The total number of shares released for the fund management plans was 712,059, with a 6-month lock-up period starting from April 20, 2023[16]. - The total number of shares subject to lock-up for the company was 213,618, with a 6-month lock-up period starting from April 20, 2023[16]. - The company issued new shares to specific investors, resulting in an increase in lock-up shares for various stakeholders[16]. - The total number of shares released during the current period reflects the company's ongoing profit distribution strategy[16]. - The company plans to continue its strategy of issuing shares to specific investors in the future, which may impact the lock-up structure[16]. Research and Development - Research and development expenses increased by 30.98% to 41,727,262.07 from 31,858,295.67 year-on-year, driven by accelerated project progress[10]. - Research and development expenses increased to CNY 41,727,262.07, up from CNY 31,858,295.67, reflecting a growth of 30.9% year-over-year[24]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[20]. - The company aims to leverage its recent capital increases to fund new product development and technological advancements[17]. Future Outlook - Future guidance indicates a commitment to improving operational efficiency and exploring strategic partnerships for growth[20]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]. - The company is focusing on strategic partnerships to enhance its market position and drive future growth[17]. - The company has outlined a clear roadmap for future expansions, supported by the recent capital raised through share issuance[17].